drugset / Trial / NCT00186329

BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

NCT00186329 ↗

Phase 4 Completed 100 enrolled Stanford University Scios, Inc. · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In this study, we plan to randomize patients with heart failure and kidney dysfunction to receive infusions of Natrecor (B-type Natriuretic Peptide)--which may be beneficial to the management of these two diseases--or placebo.

Timeline

Start
2004-03
Primary completion
—
Completion
2006-10

Outcome

Missed primary endpoint

paper There were no significant differences in the incidence of a 20% creatinine rise (23% vs. 25%) PMID 17980248 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.01 ug/kg Intravenous